Pierre-Etienne Chabrier De Lassauniere

This inventor holds 35 USPTO granted patents, plus 3 CIPO patents and 11 EPO patents, primarily in Medicinal Chemistry. Top assignees: Societe De Conseils De Recherches Et D'applications Scientifiques (s.c.r.a.s.), Ipsen Pharma S.a.s., Societe De Conseils De Recherches Et D'applications Scientifiques. Active years: 1992-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pierre-Etienne Chabrier De Lassauniere. Retrieved from https://idiyas.com/inventor/pierre-etienne-chabrier-de-lassauniere

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 35

% Patents Active = 11.4

CIPO Patents = 3

EPO Patents = 11 (Patent Applications = 2)

Average Co-Inventor Count = 3.3

ph-index = 11

Forward Citations = 285(Granted Patents)

Location History:

Bleriot, FR (2008)
Paris, FR (1992 - 2018)

Company Filing History:

19 out of 119

Societe De Conseils De Recherches Et D'applications Scientifiques (s.c.r.a.s.)

Societe De Conseils De Recherches Et D'applications Scientifiques

5. 1 out of 834,659

Other

patents

Years Active: 1992-2018

Loading Chart...

Areas of Expertise:

Thiazole Derivatives

Botulinum Neurotoxins

Amidine Derivatives

Heterocyclic Compounds

Neurotoxins

Pain Management

Therapeutic Applications

Chemical Treatments

Pharmaceutical Compositions

Inhibitors

AIDS Treatment

Dyskinesias

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9918967 - Thiazole derivatives for treating dyskinesias caused by a chemical treatment (2018-03-20),

2. 9176119 - Method for quantifying a cholinergic neurotoxin in a sample (2015-11-03),

3. 9080220 - Simultaneous, separate or sequential therapeutic use of at least one botulinum neurotoxin and of at least one opiate derivative (2015-07-14),

4. 9006274 - Thiazole derivatives for treating dyskinesias caused by a chemical treatment (2015-04-14),

5. 8921322 - Use of at least one botulinum neurotoxin for treating the pain induced by therapeutic treatments for the AIDS virus (2014-12-30),

6. 8642591 - Composition containing amidine derivatives or carboxamide derivatives and steroids, as a medicament (2014-02-04),

7. 8288560 - Derivatives of heterocycles with 5 members, their preparation and their use as medicaments (2012-10-16),

8. 8273359 - Therapeutic use of at least one botulinum neurotoxin in the treatment of pain induced by at least one anti-neoplastic agent (2012-09-25),

9. 7956075 - Derivatives of heterocycles with 5 members, their preparation and their use as medicaments (2011-06-07),

10. 7659266 - Amidine derivatives and their applications as a medicament (2010-02-09),

11. 7576241 - Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them (2009-08-18),

12. 7473779 - Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them (2009-01-06),

13. 7465721 - 2-hydroxytetrahydrofuran derivatives and use thereof as medicaments (2008-12-16),

14. 7384933 - Derivatives of 2-hydroxytetrahydrofuran and their use as medicaments (2008-06-10),

15. 7345066 - Use of thiazole derivatives for preparing a medicine for protecting mitochondria (2008-03-18),

Title: Pierre-Etienne Chabrier de Lassauniere: Innovator in Therapeutics

Introduction: Pierre-Etienne Chabrier de Lassauniere is a renowned inventor based in Paris, France, celebrated for his contributions to the pharmaceutical field. With an impressive portfolio of 33 patents, Lassauniere has made significant strides in the development of therapeutic agents.

Latest Patents: Among his latest innovations, Lassauniere has developed thiazole derivatives aimed at treating dyskinesias caused by chemical treatments. This invention focuses on the use of thiazole derivatives with a general formula for preparing medications that address the prevention and treatment of dyskinesias. Furthermore, he has devised a method for quantifying a cholinergic neurotoxin in a sample, demonstrating his commitment to advancing medical science through his inventive processes.

Career Highlights: Lassauniere has held positions in prestigious organizations such as Société de Conseils de Recherches et d'Applications Scientifiques (SCRAS) and Ipsen Pharma S.A.S., where he utilized his expertise to drive innovation in therapeutic research and development.

Collaborations: Throughout his career, Lassauniere has collaborated with notable peers, such as Serge Auvin and Jeremiah Harnett. These partnerships have propelled his research efforts and contributed to the success of his inventions in the scientific community.

Conclusion: Pierre-Etienne Chabrier de Lassauniere stands out as a visionary inventor whose work continues to influence the fields of pharmacology and toxicology. His patents reflect a dedication to improving health outcomes and enhancing our understanding of complex biological interactions.

Profile summary based on public USPTO records.